{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:04:15Z","timestamp":1779314655791,"version":"3.51.4"},"reference-count":45,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The overexpression of the Protein Tyrosine Phosphatase 1B (PTP1B), a\nkey role in the development of insulin resistance, diabetes (T2DM) and obesity, seems to have a\nsubstantial impact as a negative regulator of the insulin and leptin signaling pathways. Therefore,\ninhibiting PTP1B is a prospective therapeutic approach for the treatment of diabetes and\nobesity. However, the pyrazole scaffold is expected to be of significant pharmaceutical interest\ndue to its broad spectrum of pharmacological actions. This study aims to focus on the significance\nof pyrazole scaffold in medicinal chemistry, the impact of PTP1B in diabetes and the therapeutic\napproach of pyrazole scaffold to treat T2DM.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A comprehensive analysis of the published literature in several pharmaceutical and\nmedical databases, such as the Web of Science (WoS), PubMed, ResearchGate, ScienceDirect\netc., were indeed successfully completed and classified accordingly.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>As reviewed, the various derivatives of the pyrazole scaffold exhibited prominent\nPTP1B inhibitory activity. The result showed that derivatives of oxadiazole and dibenzyl amine,\nchloro substituents, 1, 3-diaryl pyrazole derivatives with rhodanine-3-alkanoic acid groups,\nnaphthalene and also 1, 3, 5-triazine-1H-pyrazole-triazolothiadiazole derivatives, octyl and\ntetradecyl derivative, indole- and N-phenylpyrazole-glycyrrhetinic acid derivatives with trifluoromethyl\ngroup, 2,3-pyrazole ring-substituted-4,4-dimethyl lithocholic acid derivatives with 4-\nfluoro phenyl substituted and additional benzene ring in the pyrazole scaffold significantly inhibits\nPTP1B. In silico study observed that pyrazole scaffold interacted with amino acid residues\nlike TYR46, ASP48, PHE182, TYR46, ALA217 and ILE219.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Diabetes is a metabolic disorder that elevates the risk of mortality and severe complications.\nPTP1B is a crucial component in the management of diabetes and obesity. As a result,\nPTP1B is a promising therapeutic target for the treatment of T2DM and obesity in humans. We\nconcluded that the pyrazole scaffold has prominent inhibitory potential against PTP1B.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115733998280245240130075909","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T07:25:56Z","timestamp":1707895556000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pyrazole Scaffold: Potential PTP1B Inhibitors for Diabetes Treatment"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2340-1072","authenticated-orcid":true,"given":"Kishor R.","family":"Danao","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Dadasaheb Balpande College of Pharmacy, Nagpur, Maharashtra 440037, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6248-7710","authenticated-orcid":true,"given":"Vijayshri V.","family":"Rokde","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Dadasaheb Balpande College of Pharmacy, Nagpur, Maharashtra 440037, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-6882","authenticated-orcid":true,"given":"Deweshri M.","family":"Nandurkar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Dadasaheb Balpande College of Pharmacy, Nagpur, Maharashtra 440037, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2205-2031","authenticated-orcid":true,"given":"Ujwala N.","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Dadasaheb Balpande College of Pharmacy, Nagpur, Maharashtra 440037, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/aps.2014.80","volume":"35","author":"He R.","year":"2014","unstructured":"He R.; Yu Z.; Zhang R.; Zhang Z.; Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacol Sin  2014,35(10),1227-1246","journal-title":"Acta Pharmacol Sin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ejmech.2017.11.087","volume":"144","author":"Mascarello A.","year":"2018","unstructured":"Mascarello A.; Orbem Menegatti A.C.; Calcaterra A.; Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B. Eur J Med Chem  2018,144,277-288","journal-title":"Eur J Med Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/febs.12077","volume":"280","author":"Tonks N.K.","year":"2013","unstructured":"Tonks N.K.; Protein tyrosine phosphatases - from housekeeping enzymes to master regulators of signal transduction. FEBS J  2013,280(2),346-378","journal-title":"FEBS J"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1080\/07391102.2019.1664333","volume":"38","author":"Liu W.S.","year":"2020","unstructured":"Liu W.S.; Wang R.R.; Yue H.; Design, synthesis, biological evaluation and molecular dynamics studies of 4-thiazolinone derivatives as protein tyrosine phosphatase 1B (PTP1B) inhibitors. J Biomol Struct Dyn  2020,38(13),3814-3824","journal-title":"J Biomol Struct Dyn"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3109\/10409238.2013.819830","volume":"48","author":"Feldhammer M.","year":"2013","unstructured":"Feldhammer M.; Uetani N.; Miranda-Saavedra D.; Tremblay M.L.; PTP1B: A simple enzyme for a complex world. Crit Rev Biochem Mol Biol  2013,48(5),430-445","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.2337\/diab.45.10.1379","volume":"45","author":"Seely B.L.","year":"1996","unstructured":"Seely B.L.; Staubs P.A.; Reichart D.R.; Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes  1996,45(10),1379-1385","journal-title":"Diabetes"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"19810","DOI":"10.1074\/jbc.271.33.19810","volume":"271","author":"Kenner K.A.","year":"1996","unstructured":"Kenner K.A.; Anyanwu E.; Olefsky J.M.; Kusari J.; Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling. J Biol Chem  1996,271(33),19810-19816","journal-title":"J Biol Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1365-2796.2004.01339.x","volume":"256","author":"Santaniemi M.","year":"2004","unstructured":"Santaniemi M.; Ukkola O.; Kes\u00e4niemi Y.A.; Tyrosine phosphatase 1B and leptin receptor genes and their interaction in type 2 diabetes. J Intern Med  2004,256(1),48-55","journal-title":"J Intern Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1074\/jbc.275.6.4283","volume":"275","author":"Goldstein B.J.","year":"2000","unstructured":"Goldstein B.J.; Bittner-Kowalczyk A.; White M.F.; Harbeck M.; Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J Biol Chem  2000,275(6),4283-4289","journal-title":"J Biol Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/157339913804143225","volume":"9","author":"Fu Z.","year":"2013","unstructured":"Fu Z.; Gilbert E.R.; Liu D.; Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev  2013,9(1),25-53","journal-title":"Curr Diabetes Rev"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/nrd895","volume":"1","author":"Johnson T.O.","year":"2002","unstructured":"Johnson T.O.; Ermolieff J.; Jirousek M.R.; Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov  2002,1(9),696-709","journal-title":"Nat Rev Drug Discov"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1161\/CIRCRESAHA.107.165472","volume":"102","author":"Kim J.","year":"2008","unstructured":"Kim J.; Wei Y.; Sowers J.R.; Role of mitochondrial dysfunction in insulin resistance. Circ Res  2008,102(4),401-414","journal-title":"Circ Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1128\/MCB.20.15.5479-5489.2000","volume":"20","author":"Klaman L.D.","year":"2000","unstructured":"Klaman L.D.; Boss O.; Peroni O.D.; Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol  2000,20(15),5479-5489","journal-title":"Mol Cell Biol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1074\/jbc.C117.819110","volume":"293","author":"Krishnan N.","year":"2018","unstructured":"Krishnan N.; Konidaris K.F.; Gasser G.; Tonks N.K.; A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models. J Biol Chem  2018,293(5),1517-1525","journal-title":"J Biol Chem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Zheng Y.","year":"2018","unstructured":"Zheng Y.; Ley S.H.; Hu F.B.; Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol  2018,14(2),88-98","journal-title":"Nat Rev Endocrinol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41574-021-00489-y","volume":"17","author":"Perreault L.","year":"2021","unstructured":"Perreault L.; Skyler J.S.; Rosenstock J.; Novel therapies with precision mechanisms for type 2 diabetes mellitus. Nat Rev Endocrinol  2021,17(6),364-377","journal-title":"Nat Rev Endocrinol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"115119","DOI":"10.1016\/j.ejmech.2023.115119","volume":"249","author":"Mushtaq A.","year":"2023","unstructured":"Mushtaq A.; Azam U.; Mehreen S.; Naseer M.M.; Synthetic \u03b1-glucosidase inhibitors as promising anti-diabetic agents: Recent developments and future challenges. Eur J Med Chem  2023,249,115119","journal-title":"Eur J Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"e061022209633","DOI":"10.2174\/1573399819666221006103113","volume":"19","author":"Rokde V.","year":"2023","unstructured":"Rokde V.; Danao K.; Bali N.; Mahajan U.; The severity of COVID-19 in diabetes patients. Curr Diabetes Rev  2023,19(5),e061022209633","journal-title":"Curr Diabetes Rev"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrd.2016.151","volume":"15","author":"Rines A.K.","year":"2016","unstructured":"Rines A.K.; Sharabi K.; Tavares C.D.J.; Puigserver P.; Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nat Rev Drug Discov  2016,15(11),786-804","journal-title":"Nat Rev Drug Discov"},{"key":"ref=20","year":"2021","unstructured":"IDF Diabetes Atlas International Diabetes Federation 2021","journal-title":"IDF Diabetes Atlas"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3399\/bjgp11X548884","volume":"61","author":"Seewoodhary J.","year":"2011","unstructured":"Seewoodhary J.; Bain S.C.; Novel treatments for type 2 diabetes. Br J Gen Pract  2011,61(582),5-6","journal-title":"Br J Gen Pract"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1039\/C6NJ03181A","volume":"41","author":"Ansari A.","year":"2017","unstructured":"Ansari A.; Ali A.; Asif M.; Shamsuzzaman S.; Review: Biologically active pyrazole derivatives. New J Chem  2017,41(1),16-41","journal-title":"New J Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3390\/molecules22101665","volume":"22","author":"Santos C.","year":"2017","unstructured":"Santos C.; Silva V.; Silva A.; Synthesis of chromone-related pyrazole compounds. Molecules  2017,22(10),1665","journal-title":"Molecules"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/B978-0-12-407766-9.00017-1","volume":"91","author":"Cho H.","year":"2013","unstructured":"Cho H.; Protein tyrosine phosphatase 1B (PTP1B) and obesity. Vitam Horm  2013,91,405-424","journal-title":"Vitam Horm"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ejmech.2018.07.007","volume":"156","author":"Silva V.L.M.","year":"2018","unstructured":"Silva V.L.M.; Elguero J.; Silva A.M.S.; Current progress on antioxidants incorporating the pyrazole core. Eur J Med Chem  2018,156,394-429","journal-title":"Eur J Med Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.2174\/1389557521666211101162449","volume":"22","author":"Dewi R.M.","year":"2022","unstructured":"Dewi R.M.; Megawati M.; Antika L.D.; Antidiabetic properties of dietary chrysin: A cellular mechanism review. Mini Rev Med Chem  2022,22(10),1450-1457","journal-title":"Mini Rev Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1124\/jpet.113.208728","volume":"349","author":"Panzhinskiy E.","year":"2014","unstructured":"Panzhinskiy E.; Hua Y.; Lapchak P.A.; Novel curcumin derivative CNB-001 mitigates obesity-associated insulin resistance. J Pharmacol Exp Ther  2014,349(2),248-257","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/1389557515666150203144339","volume":"15","author":"Wang L.J.","year":"2015","unstructured":"Wang L.J.; Jiang B.; Wu N.; Wang S.Y.; Shi D.Y.; Small molecules as potent protein tyrosine phosphatase 1B (PTP1B) inhibitors documented in patents from 2009 to 2013. Mini Rev Med Chem  2015,15(2),104-122","journal-title":"Mini Rev Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.bmcl.2019.03.023","volume":"29","author":"Sun L.","year":"2019","unstructured":"Sun L.; Wang P.; Xu L.; Gao L.; Li J.; Piao H.; Discovery of 1,3-diphenyl-1H-pyrazole derivatives containing rhodanine-3-alkanoic acid groups as potential PTP1B inhibitors. Bioorg Med Chem Lett  2019,29(10),1187-1193","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=30","first-page":"1223","author":"Chenglu Z.","year":"2019","unstructured":"Chenglu Z.; Chuanyin L.; Yaodong G.; Xiaona S.; Synthesis and bioactivity evaluation of novel 1, 3, 5-triazine-1h-pyrazole-triazol-ethiadiazole derivatives. Youji Huaxue  2019(38),1223-1232","journal-title":"Youji Huaxue"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.5012\/bkcs.2003.24.10.1455","volume":"24","author":"Cho S.Y.","year":"2003","unstructured":"Cho S.Y.; Ahn J.H.; Ha J.D.; Protein tyrosine phosphatase 1b inhibitors: Heterocyclic carboxylic acids. Bull Korean Chem Soc  2003,24(10),1455-1464","journal-title":"Bull Korean Chem Soc"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.3390\/molecules26144375","volume":"26","author":"De-la-Cruz-Mart\u00ednez L.","year":"2021","unstructured":"De-la-Cruz-Mart\u00ednez L.; Duran-Becerra C.; Gonz\u00e1lez-Andrade M.; Indole-and pyrazole-glycyrrhetinic acid derivatives as PTP1B inhibitors: Synthesis, in vitro and in silico studies. Molecules  2021,26(14),4375","journal-title":"Molecules"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"106551","DOI":"10.1039\/C5RA20238H","volume":"5","author":"Mao S.W.","year":"2015","unstructured":"Mao S.W.; Shuai L.; He H.B.; Synthesis and biological evaluation of novel 2,3-pyrazole ring-substituted-4,4-dimethyl lithocholic acid derivatives as selective protein tyrosine phosphatase 1B (PTP1B) inhibitors with cellular efficacy. RSC Advances  2015,5(129),106551-106560","journal-title":"RSC Advances"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"e202300394","DOI":"10.1002\/cbdv.202300394","volume":"20","author":"Nandurkar D.","year":"2023","unstructured":"Nandurkar D.; Menghani S.; Danao K.; New benzopyrrole derivatives: Synthesis and appraisal of their potential as antimicrobial agents. Chem Biodivers  2023,20(7),e202300394","journal-title":"Chem Biodivers"},{"key":"ref=35","author":"Danao K.","year":"2022","unstructured":"Danao K.; Nandurkar D.; Rokde V.; Shivhare R.; Mahajan U.; Molecular docking: Metamorphosis in drug discovery. In: Molecular Docking-Recent Advances 2022 Sep 2  2022","journal-title":"In: Molecular Docking-Recent Advances 2022 Sep 2"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e202300433","DOI":"10.1002\/cbdv.202300433","volume":"20","author":"Rokde V.","year":"2023","unstructured":"Rokde V.; Danao K.; Nimje J.; Design, synthesis, antimicrobial evaluation of novel 2\u2010Oxo\u20104\u2010substituted aryl\u2010azetidine benzotriazole derivatives**. Chem Biodivers  2023,20(7),e202300433","journal-title":"Chem Biodivers"},{"key":"ref=37","author":"Shivhare R.","year":"2022","unstructured":"Shivhare R.; Danao K.; Nandurkar D.; Schiff base as multifaceted bioactive core. In: Schiff Base in Organic  2022","journal-title":"In: Schiff Base in Organic"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.13005\/bbra\/3077","volume":"20","author":"Danao K.","year":"2023","unstructured":"Danao K.; Kale S.; Rokde V.; In silico prediction of antidiabetic activity of phytoconstituents of pterocarpus marsupium targeting \u03b1-amylase enzyme. Biosci Biotechnol Res Asia  2023,20(1),147-162","journal-title":"Biosci Biotechnol Res Asia"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"103927","DOI":"10.1016\/j.bioorg.2020.103927","volume":"100","author":"Rocha R.F.","year":"2020","unstructured":"Rocha R.F.; Rodrigues T.; Menegatti A.C.O.; Bernardes G.J.L.; Terenzi H.; The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activity. Bioorg Chem  2020,100,103927","journal-title":"Bioorg Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1517\/13543776.2014.947268","volume":"24","author":"Tamrakar A.K.","year":"2014","unstructured":"Tamrakar A.K.; Maurya C.K.; Rai A.K.; PTP1B inhibitors for type 2 diabetes treatment: A patent review (2011 \u2013 2014). Expert Opin Ther Pat  2014,24(10),1101-1115","journal-title":"Expert Opin Ther Pat"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1534-5807(02)00148-X","volume":"2","author":"Zabolotny J.M.","year":"2002","unstructured":"Zabolotny J.M.; Bence-Hanulec K.K.; Stricker-Krongrad A.; PTP1B regulates leptin signal transduction in vivo. Dev Cell  2002,2(4),489-495","journal-title":"Dev Cell"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bioorg.2016.12.004","volume":"70","author":"Verma M.","year":"2017","unstructured":"Verma M.; Gupta S.J.; Chaudhary A.; Garg V.K.; Protein tyrosine phosphatase 1B inhibitors as antidiabetic agents - A brief review. Bioorg Chem  2017,70,267-283","journal-title":"Bioorg Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1038\/srep05095","volume":"4","author":"Liu M.","year":"2014","unstructured":"Liu M.; Wang L.; Sun X.; Zhao X.; Investigating the impact of Asp181 point mutations on interactions between PTP1B and phosphotyrosine substrate. Sci Rep  2014,4(1),5095","journal-title":"Sci Rep"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bmc.2016.10.012","volume":"25","author":"Basu S.","year":"2017","unstructured":"Basu S.; Prathipati P.; Thorat S.; Rational design, synthesis, and structure-activity relationships of 5-amino-1H-pyrazole-4-carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem  2017,25(1),67-74","journal-title":"Bioorg Med Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ddstr.2005.05.002","volume":"2","author":"Montalibet J.","year":"2005","unstructured":"Montalibet J.; Kennedy B.P.; Therapeutic strategies for targeting PTP1B in diabetes. Drug Discov Today Ther Strateg  2005,2(2),129-135","journal-title":"Drug Discov Today Ther Strateg"}],"container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733998280245240130075909","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/226925\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733998280245240130075909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T08:52:07Z","timestamp":1730278327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/226925\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115733998280245240130075909","relation":{},"ISSN":["1573-3998"],"issn-type":[{"value":"1573-3998","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-09-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e130224226925"}}